- Home
- FCEL vs EDIT Comparison
FCEL vs EDIT Comparison
Compare FCEL & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCEL
- EDIT
- Stock Information
- Founded
- FCEL 1969
- EDIT 2013
- Country
- FCEL United States
- EDIT United States
- Employees
- FCEL N/A
- EDIT N/A
- Industry
- FCEL Industrial Machinery/Components
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FCEL Energy
- EDIT Health Care
- Exchange
- FCEL Nasdaq
- EDIT Nasdaq
- Market Cap
- FCEL 273.9M
- EDIT 269.8M
- IPO Year
- FCEL 1992
- EDIT 2016
- Fundamental
- Price
- FCEL $7.92
- EDIT $3.77
- Analyst Decision
- FCEL Hold
- EDIT Buy
- Analyst Count
- FCEL 5
- EDIT 11
- Target Price
- FCEL $8.13
- EDIT $4.56
- AVG Volume (30 Days)
- FCEL 4.6M
- EDIT 3.1M
- Earning Date
- FCEL 09-09-2025
- EDIT 10-31-2025
- Dividend Yield
- FCEL N/A
- EDIT N/A
- EPS Growth
- FCEL N/A
- EDIT N/A
- EPS
- FCEL N/A
- EDIT N/A
- Revenue
- FCEL $152,472,000.00
- EDIT $38,901,000.00
- Revenue This Year
- FCEL $34.68
- EDIT N/A
- Revenue Next Year
- FCEL $25.52
- EDIT N/A
- P/E Ratio
- FCEL N/A
- EDIT N/A
- Revenue Growth
- FCEL 78.81
- EDIT N/A
- 52 Week Low
- FCEL $3.58
- EDIT $0.91
- 52 Week High
- FCEL $13.98
- EDIT $4.54
- Technical
- Relative Strength Index (RSI)
- FCEL 45.61
- EDIT 53.50
- Support Level
- FCEL $7.47
- EDIT $3.48
- Resistance Level
- FCEL $11.99
- EDIT $4.27
- Average True Range (ATR)
- FCEL 0.94
- EDIT 0.38
- MACD
- FCEL -0.41
- EDIT -0.06
- Stochastic Oscillator
- FCEL 9.51
- EDIT 35.74
About FCEL FuelCell Energy Inc.
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products and electrolysis platforms that decarbonize power and produce hydrogen. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company operates in USA, South Korea, Europe and Canada. Majority of revenue is from USA and South Korea.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.